Feedback
Settings

Settings

Goto Application

1. CZ294029 - Analogue of GLP-1, use thereof and pharmaceutical composition in which the analogue is comprised

PermaLink
Office Czech Republic
Application Number 2001-1748
Application Date 07.12.1999
Publication Number 294029
Publication Date 15.09.2004
Grant Number 294029
Grant Date 15.09.2004
Publication Kind B6
IPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 9/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
12Antihypertensives
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 11/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
04for throat disorders
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
CPC
C07K 14/605
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
605Glucagons
A61P 19/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
10for osteoporosis
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 5/44
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
38of the suprarenal hormones
44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
A61P 5/48
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
48of the pancreatic hormones
A61P 5/50
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
5Drugs for disorders of the endocrine system
48of the pancreatic hormones
50for increasing or potentiating the activity of insulin
Applicants IPSEN PHARMA S.A.S.
Inventors Zheng Xin Dong
Agents PATENTSERVIS PRAHA a.s.
Priority Data 1998 111255 07.12.1998 US
10002066 30.10.2001 US
Title
(CS) Analog GLP-1, jeho použití a farmaceutický prostředek jej obsahující
(EN) Analogue of GLP-1, use thereof and pharmaceutical composition in which the analogue is comprised
Abstract
(CS)
Peptidový analog glukagonu GLP-1, jeho farmakologicky přijatelné soli, metody použití takového analogu, farmaceutické prostředky, které tento analog obsahují pro léčení savců, zejména léčení diabetes typu I a II.

(EN)
The present invention is directed to peptide analogue of glucagon-like peptide-1, the pharmaceutically acceptable salts thereof, to methods of using such analogue to treat mammals, particularly to treat diabetes mellitus of the type I and II.
Also published as
CA2778047
NO20032093
ES2230912
AR021576
RU02288232
CN1495198
CN1935839
DE000069922043
PT1137667
SG81416
EP1137667
EP1359159
EP2322545
RU02214418
CN1329620
CA2353574
AU2000019736
DK1137667
JP2002531578
CZ295044
CZ295889
CZ295768
CZ295890
CZ295891
WO/2000/034331
NZ511931
IL143346
ZA200104478
ZA2001/04478
ININ/PCT/2001/782/CHE
MXPA/a/2001/005762
KR1020010080713
NO20012786
US20030101904
US6903186
EP1308490
DE000060213938
AU2003202533
AR040228
US20040018981
JP2004131473
KR1020040053220
JP2005132845
KR1020050037004
US20050233969
AU2005203169
JP2006151988
AR057639
US20080108566
JP2008001710
US20090197802
IL187907
AR076950
# -